Essential thrombocythemia at diagnosis: causes of diagnostic evaluation and presence of positive diagnostic findings

被引:30
作者
Jantunen, R
Juvonen, E
Ikkala, E
Oksanen, K
Anttila, P
Hormila, P
Jansson, SE
Kekomaki, R
Ruutu, T
机构
[1] Univ Helsinki, Cent Hosp, Dept Med, FIN-00290 Helsinki, Finland
[2] Kanta Hame Cent Hosp, FIN-13530 Hameenlinna, Finland
[3] Helsinki Municipal Hosp, FIN-00180 Helsinki, Finland
[4] Jorvi Hosp, FIN-02740 Espoo, Finland
[5] Univ Helsinki, Dept Clin Chem, SF-00100 Helsinki, Finland
[6] Finnish Red Cross & Blood Transfus Serv, FIN-00310 Helsinki, Finland
关键词
essential thrombocythemia; myeloproliferative disorders; thrombocytosis; megakaryocyte progenitors; erythroid progenitors;
D O I
10.1007/s002770050423
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The reasons for diagnostic evaluation and the clinical and laboratory data at diagnosis of 170 patients with essential thrombocythemia (ET) were studied retrospectively. The age distribution was 19-88 years (median 52 years), and 52 patients were under the age of 45 years. In 111 patients (65%) thrombocytosis was a chance finding, but the past history of 37 of these patients revealed symptoms known to be related to ET. The diagnosis was based on a chance finding in a significantly higher proportion of female (74%) than male (53%) patients. The diagnosis of ET is based mostly on negative findings, i.e., on the exclusion of other causes of thrombocytosis, and positive diagnostic tests would be useful. We evaluated the presence of positive diagnostic findings of myeloproliferative disorders in ET. Splenomegaly was seen in 26% and an abnormal karyotype in 5% of the patients. Abnormal megakaryocyte morphology was seen in 80%, abnormal in vitro growth of hematopoietic progenitors in 74%, and abnormal platelet function in 83% of the patients. Both in vitro cultures of hematopoietic progenitors and platelet functions were studied in 36 patients, and in only two of these were both tests normal. We conclude that in most patients with ET the diagnosis can be strongly supported by positive findings, especially by in vitro cultures of hematopoietic progenitors and studies of platelet function.
引用
收藏
页码:101 / 106
页数:6
相关论文
共 21 条
[1]  
BELLUCCI S, 1986, CANCER, V58, P2440, DOI 10.1002/1097-0142(19861201)58:11<2440::AID-CNCR2820581115>3.0.CO
[2]  
2-Y
[3]   OCCURRENCE, ETIOLOGY, AND CLINICAL-SIGNIFICANCE OF EXTREME THROMBOCYTOSIS - A STUDY OF 280 CASES [J].
BUSS, DH ;
CASHELL, AW ;
OCONNOR, ML ;
RICHARDS, F ;
CASE, LD .
AMERICAN JOURNAL OF MEDICINE, 1994, 96 (03) :247-254
[4]  
COLOMBI M, 1991, CANCER-AM CANCER SOC, V67, P2926, DOI 10.1002/1097-0142(19910601)67:11<2926::AID-CNCR2820671136>3.0.CO
[5]  
2-3
[6]  
CORTELAZZO S, 1980, THROMB HAEMOSTASIS, V43, P127
[7]  
DUDLEY JM, 1989, BRIT J HAEMATOL, V71, P331
[8]   THE POSSIBLE VALUE OF PLATELET-AGGREGATION STUDIES IN PATIENTS WITH INCREASED PLATELET NUMBER [J].
FABRIS, F ;
RANDI, M ;
SBROJAVACCA, R ;
CASONATO, A ;
GIROLAMI, A .
BLUT, 1981, 43 (05) :279-285
[9]  
FENAUX P, 1990, CANCER, V66, P549, DOI 10.1002/1097-0142(19900801)66:3<549::AID-CNCR2820660324>3.0.CO
[10]  
2-6